Docoh
Loading...

CMPI Checkmate Pharmaceuticals

APP
Utility
Packaging Oligonucleotides into Virus-like Particles
26 Aug 21
The present invention relates to processes for producing compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle.
Evan David WALTERS, Frank HENNECKE
Filed: 8 Apr 19
APP
Utility
Synthetic Rig-i-like Receptor Agonists
8 Jul 21
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
Arthur M. KRIEG, Aaron Jay MORRIS
Filed: 23 Dec 20
APP
Utility
Compositions and Methods for Tumor Immunotherapy
4 Feb 21
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody.
Arthur Krieg, Aaron Morris, David Mauro, George Weiner, Mohammed Milhem
Filed: 12 Feb 19
GRANT
Utility
Synthetic RIG-I-like receptor agonists
2 Feb 21
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
Arthur M. Krieg, Aaron Jay Morris
Filed: 19 Apr 19
APP
Utility
Combination Tumor Immunotherapy
9 Sep 20
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CLA-4 antibody.
Arthur Krieg
Filed: 4 May 20
GRANT
Utility
Combination tumor immunotherapy
15 Jun 20
Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody.
Arthur M. Krieg
Filed: 21 Dec 15
APP
Utility
Synthetic Rig-i-like Receptor Agonists
26 Feb 20
The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).
Arthur M. KRIEG, Aaron Jay MORRIS
Filed: 18 Apr 19
  • 1
Patents are sorted by USPTO publication date, most recent first